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ABSTRACT
We recently demonstrated that the 3-kb 5'-flanking region of the human Robo4 gene directs endothelial cell-specific expression in vitro and in vivo. Moreover, a GA binding protein (GABP)-binding motif at -119 was necessary for mediating promoter activity in vitro. The goal of the present study was to confirm the functional relevance of the -119 GABP-binding site in vivo. To that end, the Hprt locus of mice was targeted with a Robo4-LacZ transgenic cassette in which the GABP site was mutated. In other studies, the GABP mutation was introduced into the endogenous mouse Robo4 locus in which LacZ was knocked in. Compared to their respective controls, the mutant promoters displayed a significant reduction in activity in embryoid bodies, embryos and adult animals. Together, these data provide strong support for the role of the GABP-binding motif in mediating Robo4 expression in the intact endothelium. 
MATERIALS AND METHODS
The generation of Hprt-targeted and knock-in mice with and without a mutation of the -119 ETS motif is detailed in the Online Data Supplement. β-galactosidase activity assays, embryoid body preparations, and generation of tumor xenografts are also described in the Online Data Supplement. 
RESULTS AND DISCUSSION
We have demonstrated a critical role for an ETS site at -119 (which we designated -119 ETS(1)) in mediating Robo4 expression in vitro ( 4 and Supplemental Data). To determine the role of the -119 ETS(1) motif in directing expression of Robo4 in vivo, we generated a Robo4-LacZ transgenic cassette in which the ETS(1) of the human Robo4 promoter was mutated (Fig. 1A) . A single copy of the transgenic cassette was targeted to the Hprt locus of mice using homologous recombination as was previously described for the wildtype Robo4 promoter 4 . High percentage chimeric males were bred to wild-type females.
Resulting female agouti offspring were bred to generate stable lines. Reporter gene activity was assayed in 6-8-week old F2 males. As shown in To provide further evidence for the in vivo role of the -119 ETS(1) site, we introduced the same mutation into the endogenous Robo4 promoter and replaced the Robo4 gene only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From 6 with LacZ ( Fig. 2A) . Reporter gene activity was assayed in 6-8-week old F2 males and compared with that of age-and gender-matched mice in which the LacZ was knocked into the wild-type Robo4 locus. Expression of LacZ was greater in microvascular endothelium compared with endothelial cells of large arteries or veins. For example, whole mount LacZ stains of the diaphragm revealed widespread microvascular expression, whereas the X-Gal reaction product in the aorta was limited to branch points (Fig. 2B, arrowheads) . Similar to the results of the Hprt-targeted mice, a mutation of the GABP-binding site in the endogenous locus resulted in reduced expression in the blood vessels of all organs examined (Fig. 2B) . To quantitate these differences, the tissues were assayed for β-galactosidase activity. As shown in Fig. 2C , β-galactosidase activity was significantly reduced in the brain (25% of wild-type), heart (28%), lung (25%), liver (52%), and kidney (24%). In immunofluorescent studies, LacZ expression co-localized with CD31 and was significantly reduced in the GABP mutant (Fig. 2D shows brain) . In tumor xenografts, the wild-type promoter drove expression in endothelial cells, an effect that was markedly reduced in mice carrying the mutant promoter (Fig. 2E) . When corrected for VE-cadherin or CD31 expression, wild-type LacZ expression in tumors was similar to that of the liver, lung, heart and skeletal muscle (data not shown). In whole mounts of E10 embryos, the mutant promoter demonstrated significantly less LacZ expression compared with wild-type controls (Fig. 2F, upper panel) . In keeping with these results, day 10 EBs derived from ES cells targeted with the wild-type, but not mutant, Robo4 promoter exhibited a vascular pattern of β -galactosidase activity (Fig. 2E, 
lower panel).
only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From Consensus ETS binding motifs have been identified within the promoters of several endothelial cell-restricted genes, including Flk-1, Flt-1, Tie1, Tie2, and VE-cadherin [5] [6] [7] [8] [9] [10] [11] .
In some cases, the functional relevance of ETS motifs in mediating endothelial cell gene expression in vivo has been demonstrated using standard transgenic mice. For example, ETS mutations of the Tie-1 gene resulted in decreased EC expression in most organs 7 .
Mutation of ETS sites in a 4.66-kb fragment of the Mef2C gene disrupted endothelial expression in embryos 12 . In other cases, ETS sites have been shown to play a functional role in vitro, but not in transgenic mice 10, 11 . Such discordance underscores the importance of validating promoter activity in vivo. In standard transgenesis, variation in copy number and integration site may lead to significant line-to-line differences in expression. To control for these variables, we routinely employ a targeting approach in which a single copy of a transgene is inserted to a defined locus (the Hprt locus) via homologous recombination (reviewed in 13 ) . Using this approach, we previously demonstrated that mutation of several ETS motifs in the Tie-2 promoter reduced promoter activity in adult endothelium of all organs except the brain 8 . Here, we have used the Hprt-targeting strategy to demonstrate an important role for the -119 ETS (1) motif in mediating Robo4 expression in multiple vascular beds.
One drawback of both standard transgenic and Hprt-locus-targeting approaches is that a pre-defined fragment of the promoter is introduced into a foreign genomic locus where it is subject to the influence of heterologous chromatin. Although the data from these studies provide powerful proof of principle for vascular-bed-specific gene regulation, ultimate proof for the involvement of one or another cis-regulatory element (or DNA For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From
